首页> 外国专利> Ca2+ dependent monoclonal antibody against protein C, hybridoma cell line for production of the antibody, method of isolation of protein C, method of producing the antibody and polypeptide for use in the method

Ca2+ dependent monoclonal antibody against protein C, hybridoma cell line for production of the antibody, method of isolation of protein C, method of producing the antibody and polypeptide for use in the method

机译:针对C蛋白的Ca2 +依赖性单克隆抗体,用于制备该抗体的杂交瘤细胞系,分离C蛋白的方法,该抗体的制备方法以及用于该方法的多肽

摘要

A Ca2+ dependent monoclonal antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the protein C. The antibody does not bind to activated protein C and can be used to inhibit activation of protein C by thrombin-thrombomodulin. The antibody can be isolated from cell culture or ascites fluid in large quantities by affinity chromatography with mild conditions using the peptide bound to an immobilized substrate. The antibody has a number of specific uses in isolation and characterization of protein C and as a model for the design of Ca2+ dependent antibodies for the isolation of other proteins, as a diagnostic, and as a therapeutic to prevent activation of protein C. The protein c can be naturally produced or produced by expression of the recombinant gene. Advantages of the antibody in purification of protein C include the specificity for protein C and not activated protein C, and the unique Ca2+-peptide binding specificity which allows the binding site to be protected when it is being immobilized on the chromatographic support. In vivo, the antibody has been demonstrated to inhibit tumor growth. The antibody can also be used to promote clotting in patients having high levels of Factor VIII inhibitors.
机译:Ca 2+依赖性单克隆抗体,可与蛋白C的激活区域中的特定十二个肽序列(EDQVDPRLIDGK)特异性结合。该抗体不与激活的C蛋白结合,可用于通过以下方式抑制蛋白C的激活:凝血酶-血栓调节蛋白。可以通过在温和条件下使用结合到固定底物上的肽通过亲和色谱从细胞培养物或腹水中大量分离抗体。该抗体在蛋白C的分离和表征中具有许多特定用途,并作为设计Ca 2+依赖性抗体的模型来分离其他蛋白,作为诊断和预防蛋白活化的治疗方法C.蛋白c可以天然产生或通过重组基因的表达产生。抗体在纯化蛋白C方面的优势包括对蛋白C而非活化蛋白C的特异性,以及独特的Ca 2+-肽结合特异性,使该结合位点固定在色谱支持物上时可以得到保护。在体内,已证明该抗体抑制肿瘤生长。该抗体还可用于促进凝血因子VIII抑制剂水平高的患者的凝血。

著录项

  • 公开/公告号DK171826B1

    专利类型

  • 公开/公告日1997-06-23

    原文格式PDF

  • 申请/专利权人 OKLAHOMA MEDICAL RESEARCH FOUNDATION;

    申请/专利号DK19900002090

  • 发明设计人 ESMON CHARLES T.;ESMON NAOMI L.;

    申请日1990-08-30

  • 分类号G01N33/577;G01N33/68;C07K16/18;

  • 国家 DK

  • 入库时间 2022-08-22 03:27:24

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号